| 254.49 0.1 (0.04%) | 07-17 16:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 305.59 | 1-year : | 356.93 |
| Resists | First : | 261.64 | Second : | 305.59 |
| Pivot price | 251.83  |
|||
| Supports | First : | 233.04 | Second : | 215.36 |
| MAs | MA(5) : | 249.18 |
MA(20) : | 246.83 |
| MA(100) : | 220.29 |
MA(250) : | 217.53 |
|
| MACD | MACD : | 6.7 |
Signal : | 7.6 |
| %K %D | K(14,3) : | 58.4 |
D(3) : | 53.6 |
| RSI | RSI(14): 64.3 |
|||
| 52-week | High : | 261.64 | Low : | 180.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ABBV ] has closed below upper band by 34.2%. Bollinger Bands are 24.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 261.32 - 262.57 | 262.57 - 263.71 |
| Low: | 251.21 - 252.67 | 252.67 - 253.99 |
| Close: | 252.12 - 254.48 | 254.48 - 256.63 |
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Fri, 17 Jul 2026
AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe - Yahoo Finance UK
Fri, 17 Jul 2026
AbbVie granted EU nod for Boey anti-wrinkle therapy (ABBV:NYSE) - Seeking Alpha
Thu, 16 Jul 2026
Is AbbVie Inc (ABBV) Overvalued After 4.2% Rally? GF Value Says - GuruFocus
Thu, 16 Jul 2026
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter? - TradingView
Thu, 16 Jul 2026
Why AbbVie (ABBV) Stock Is Up Today - Quiver Quantitative
Thu, 16 Jul 2026
AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send? - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,770 (M) |
| Shares Float | 1,760 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 76.8 (%) |
| Shares Short | 21,900 (K) |
| Shares Short P.Month | 23,160 (K) |
| EPS | 2.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.77 |
| Profit Margin | 5.7 % |
| Operating Margin | 32.1 % |
| Return on Assets (ttm) | 10 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 12.3 % |
| Gross Profit (p.s.) | 25.56 |
| Sales Per Share | 35.49 |
| EBITDA (p.s.) | 16.9 |
| Qtrly Earnings Growth | -46.3 % |
| Operating Cash Flow | 21,220 (M) |
| Levered Free Cash Flow | 20,810 (M) |
| PE Ratio | 125.36 |
| PEG Ratio | 0.4 |
| Price to Book value | -67.51 |
| Price to Sales | 7.17 |
| Price to Cash Flow | 21.22 |
| Dividend | 1.73 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|